CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerhouse Dispensary Smoking Scholars

4 months ago

With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised…

Bausch Health to Announce Third Quarter 2025 Results on October 29

4 months ago

LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025…

AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection

4 months ago

Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditionsGenerating actionable insights into how cardiac responses…

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

4 months ago

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market

4 months ago

Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwideVANCOUVER, British Columbia, Sept. 30, 2025…

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

4 months ago

Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of…

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market

4 months ago

VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the…

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

4 months ago

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and…

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

4 months ago

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…